Current Assets
Cash & Equivalents
United Therapeutics Cash & Equivalents decreased by 17.8% to $1.28B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 32.6%, from $1.90B to $1.28B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 16.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ4 2013
Last reportedQ1 2026
How to read this metric
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
Peer comparison
A universal metric for assessing a company's immediate financial health.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $942.20M | $908.50M | $894.80M | $813.30M | $795.20M | $966.80M | $961.20M | $1.16B | $1.07B | $1.11B | $1.21B | $1.25B | $1.36B | $1.55B | $1.70B | $1.90B | $1.59B | $1.34B | $1.56B | $1.28B |
| QoQ Change | — | -3.6% | -1.5% | -9.1% | -2.2% | +21.6% | -0.6% | +21.0% | -8.3% | +3.8% | +9.0% | +3.6% | +8.3% | +14.6% | +9.2% | +11.9% | -16.1% | -15.9% | +16.2% | -17.8% |
| YoY Change | — | — | — | — | -15.6% | +6.4% | +7.4% | +43.1% | +34.2% | +14.6% | +25.6% | +7.6% | +27.0% | +40.3% | +40.5% | +51.8% | +17.5% | -13.8% | -8.3% | -32.6% |
Range$795.20M – $1.90B
CAGR+6.7%
Avg YoY Growth+15.4%
Median YoY Growth+16.0%
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is United Therapeutics's cash & equivalents?
- United Therapeutics (UTHR) reported cash & equivalents of $1.28B in Q1 2026.
- How has United Therapeutics's cash & equivalents changed year-over-year?
- United Therapeutics's cash & equivalents decreased by 32.6% year-over-year, from $1.90B to $1.28B.
- What is the long-term trend for United Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), United Therapeutics's cash & equivalents has grown at a 16.1% compound annual growth rate (CAGR), from $738.70M to $1.56B.
- What does cash & equivalents mean?
- Cash and highly liquid assets that can be converted to cash within 90 days.